References
- De Haas SL, Schoemaker RC, van Gerven JM, Hoever P, Cohen AF, Dingemanse J. Pharmacokinetics, pharmacodynamics and the pharmacokinetic/ pharmacodynamic relationship of zolpidem in healthy subjects. J Psychopharmacol 2010;24:1619-1629. https://doi.org/10.1177/0269881109106898
- Toner LC, Tsambiras BM, Catalano G, Catalano MC, Cooper DS. Central nervous system side effects associated with zolpidem treatment. Clin Neuropharmacol 2000;23: 54-58. https://doi.org/10.1097/00002826-200001000-00011
- Brodeur MR, Stirling AL. Delirium associated with zolpidem. Ann Pharmacother 2001;35:1562-1564. https://doi.org/10.1345/aph.10385
- Paradis CM, Siegel LA, Kleinman SB. Two cases of zolpidem- associated homicide. Prim Care Companion CNS Disord 2012;14. pii: PCC.12br01363.
- Kang DY, Park S, Rhee CW, et al. Zolpidem use and risk of fracture in elderly insomnia patients. J Prev Med Public Health 2012;45:219-226. https://doi.org/10.3961/jpmph.2012.45.4.219
- Kolla BP, Lovely JK, Mansukhani MP, Morgenthaler TI. Zolpidem is independently associated with increased risk of inpatient falls. J Hosp Med 2013;8:1-6. https://doi.org/10.1002/jhm.1985
- Kim YM, Lee SR, Jung JY, et al. Incidence and Risk Factors of Zolpidem-Induced Delirium. Korean J Med 2013;84: 804-809. https://doi.org/10.3904/kjm.2013.84.6.804
- FDA requires lower dosing of zolpidem. Med Lett Drugs Ther 2013;55:5.
Cited by
- 황칠(黃漆) 약침이 정신 스트레스를 받은 백서의 수면 관련 호르몬, 인지에 미치는 영향 vol.30, pp.4, 2019, https://doi.org/10.7231/jon.2019.30.4.341